FDA issues a CRL for linvoseltamab’s BLA in R/R multiple myeloma that has progressed after at least three prior therapies August 27, 2024
Sarclisa induction treatment demonstrated significantly improved PFS in patients with newly diagnosed multiple myeloma eligible for transplant August 13, 2024
DARZALEX FASPRO® (daratumumab & hyaluronidase-fihj)-based quadruplet regimen approved in the US for patients with newly diagnosed transplant-eligible multiple myeloma August 7, 2024
Blenrep (belantamab mafodotin) combinations in multiple myeloma application accepted for review by the EMA July 30, 2024
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in OS in landmark CARTITUDE-4 study July 9, 2024
100% Partial Response or Better Announced in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Ph 1b Trial June 25, 2024
Sarclisa Accepted For FDA Priority Review For The Treatment Of Transplant-Ineligible Newly Diagnosed Multiple Myeloma June 4, 2024
CARVYKTI (ciltacabtagene autoleucel) Approved by the European Commission for 2L Treatment of Patients with R/R Multiple Myeloma May 1, 2024
U.S. FDA Approves Abecma for Triple-Class Exposed R/R Multiple Myeloma After Two Prior Lines of Therapy April 8, 2024
CARVYKTI® Approved by the U.S. FDA for Patients with R/R Multiple Myeloma Who Have Received at Least One Prior Line of Therapy April 8, 2024
NMPA approves IND application for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma April 2, 2024
FDA ODAC recommends CARVYKTI® (ciltacabtagene autoleucel) for the earlier treatment of patients with R/R multiple myeloma March 26, 2024
Abecma (idecabtagene vicleucel) Approved in the European Union in Earlier Lines for Triple-Class Exposed R/R Multiple Myeloma March 26, 2024
FDA Advisory Committee Votes in Favor of Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy March 19, 2024
FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma March 19, 2024
Positive results announced from DREAMM-8 Ph 3 trial for Blenrep versus SoC combo in R/R multiple myeloma March 12, 2024
Application submitted to the EMA for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma March 12, 2024
